Anti-Tumor Necrosis Factor Alpha Treatment and Tuberculin Skin Test

Anti-Tumor Necrosis Factor Alpha Treatment and Tuberculin Skin Test

Purpose: The use of anti-tumor necrosis factor alpha (anti-TNF) drugs has been a milestone in the treatment of rheumatic diseases. Despite their strong efficacy, there are some factors restricting the use of anti-TNF agents. We must be careful especially for the granulomatous diseases which can be s...

Full description

Bibliographic Details
Main Authors:	Emine Duygu Ersozlu Bozkirli, Muge Aydin Tufan, Lale Ozisik,Nazan sen, Ahmet Eftal Yucel
Format:	Article
Language:	English
Published:	Cukurova University 2015-09-01
Series:	Çukurova Üniversitesi Tıp Fakültesi Dergisi
Subjects:	TNF tuberculin skin test tuberculosis ankylosing spondylitis rheumatoid arthritis spondyloarthropathy
Online Access:	http://www.scopemed.org/fulltextpdf.php?mno=184247

Similar Items

Anti-Tümör Nekroz Faktör Alfa Tedavisi ve Tüberkülin Cilt Testi
by: Emine Duygu BOZKIRLI, et al.
Published: (2015-09-01)

The Risk and Predictors of Malignancies in Ankylosing Spondylitis Patients in Israel—A Retrospective Electronic Data-Based Study
by: Polina Kagan, et al.
Published: (2023-08-01)

Six-Month Follow-Up of Periodontal Condition in Rheumatoid Arthritis and Ankylosing Spondylitis Arthritis Patients Undergoing Anti-Tumour Necrosis Factor-α Therapy
by: Ildikó Tar, et al.
Published: (2024-01-01)

Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?
by: Nadia Emi Aikawa, et al.
Published: (2011-01-01)

Cohort identification of axial spondyloarthritis in a large healthcare dataset: current and future methods
by: Jessica A. Walsh, et al.
Published: (2018-09-01)

Letter to the editor re: prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis
by: Rodrigo Garcia-Salinas, et al.
Published: (2021-05-01)

Prevalence, demographics, and clinical characteristics of Latin American patients with spondyloarthritis
by: Gustavo Citera, et al.
Published: (2021-01-01)

Retrospective Comparison of the Effect of IL-17 Blocker Therapy and Anti-TNF Agent Therapy on Bone Mineral Density in Axial Spondyloartropathy Patients
by: Nur Ferhatlar, et al.
Published: (2023-08-01)

A Three Year Retrospective Analysis Of Anti-Tnf Treatment Outcomes In Rheumatoid Arthritis And Ankylosing Spondylitis Patients
by: İrem Bilgetekin, et al.
Published: (2020-09-01)

Classical and paradoxical effects of TNF-α on bone homeostasis
by: Bilal eOsta, et al.
Published: (2014-02-01)

Novel insights into the anatomy and histopathology of the sacroiliac joint and correlations with imaging signs of sacroiliitis in case of axial spondyloarthritis
by: Clément Prati, et al.
Published: (2023-05-01)

Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis
by: Raphael Micheroli, et al.
Published: (2017-07-01)

Assessment of clinical profile of patients with non-radiographic axial spondyloarthropathy in a tertiary health-care center
by: Saurabh Limaye, et al.
Published: (2022-12-01)

Persistence to subcutaneous biological agents in Hungarian patients treated for inflammatory arthritis
by: Takacs P, et al.
Published: (2019-01-01)

The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis
by: Natalia P. Machado, et al.
Published: (2013-09-01)

Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFα drugs
by: F.M. Perrotta, et al.
Published: (2014-11-01)

BASELINE INFLAMMATORY MARKERS AND DISEASE ACTIVITY INDICES PREDICT TAPERING OF BIOLOGIC AGENTS IN ANKYLOSING SPONDYLITIS
by: Marius Trandafir, et al.
Published: (2018-03-01)

Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors
by: Andrea Y. Shimabuco, et al.
Published: (2018-12-01)

Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology
by: Diána Simon, et al.
Published: (2024-03-01)

Why golimumab in the treatment of psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis?
by: M. Rossini, et al.
Published: (2015-03-01)

Effect of subcutaneous high-dose methotrexate treatment on the management of rheumatoid arthritis
by: Müge Aydın Tufan, et al.
Published: (2021-09-01)

Newly diagnosed seropositive rheumatoid arthritis in a 52-year-old man superimposed on long-standing ankylosing spondylitis during secukinumab treatment
by: Jaroslaw Nowakowski, et al.
Published: (2023-10-01)

Coexistence of rheumatoid arthritis and ankylosing spondylitis
by: Tacjana Anna Barczyńska, et al.
Published: (2015-12-01)

Inhibition of spinal bone formation in AS: 10 years after comparing adalimumab to OASIS
by: Désirée van der Heijde, et al.
Published: (2019-11-01)

EFFICACY DIFFERENCES BETWEEN CLASSICAL AND BIOLOGICAL TREATMENT IN ANKYLOSING SPONDYLITIS
by: Claudiu Popescu, et al.
Published: (2016-09-01)

Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study
by: Bora Nam, et al.
Published: (2021-02-01)

The spiritual well-being of patients with ankylosing spondylitis and rheumatoid arthritis
by: Raikan Buyukavci, et al.
Published: (2022-03-01)

A combination of two or more unhealthy lifestyle factors is associated with impaired physical and mental health in patients with spondyloarthritis: a cross-sectional study
by: Elisabeth Mogard, et al.
Published: (2022-05-01)

Optimization of HLA-B*27 ALLELE Genotyping by PCR-SSP
by: Fernanda Formaggi Lara-Armi, et al.
Published: (2020-10-01)

Tuberculin skin test conversion in patients under treatment with anti-tumor necrotizing factor alpha agents
by: Mohammad-Esmaeil Hejazi, et al.
Published: (2020-07-01)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
by: M. Elaine Husni, et al.
Published: (2022-03-01)

Ankylosing Spondylitis: Review of Clinical Features, Diagnosis, and Treatment
by: Szymon Markowiak, et al.
Published: (2024-01-01)

Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis
by: Sizheng Steven Zhao, et al.
Published: (2019-07-01)

Stable high interleukin-17A concentration in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitors during a year
by: I Z Gaydukova, et al.
Published: (2017-04-01)

Coexistence of Ankylosing Spondylitis and Multiple Sclerosis: Trigger with TNF-alpha Antagonist Therapy or Coincidental?
by: Bahar Say, et al.
Published: (2019-09-01)

TEMPOROMANDIBULAR JOINT INVOLVEMENT IN RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS: A CROSS-SECTIONAL STUDY
by: Cristina Iordache, et al.
Published: (2018-01-01)

Splenic tuberculosis in a patient with ankylosing spondylitis treated with adalimumab
by: M. Fernandes, et al.
Published: (2011-11-01)

Predictors of Ophthalmic Manifestations in Patients with Ankylosing Spondylitis
by: Daria A. Karpova, et al.
Published: (2022-09-01)

DISEASE ACTIVITY INDICES AND C-REACTIVE PROTEIN PREDICT SWITCHING OF THE FIRST BIOLOGICAL AGENT IN ANKYLOSING SPONDYLITIS PATIENTS – A SINGLE-CENTER OBSERVATIONAL STUDY
by: Marius Trandafir, et al.
Published: (2017-09-01)

Relationship between periodontal status and disease activity in patients with ankylosing spondylitis
by: Ayşe Ünal Enginar, et al.
Published: (2021-02-01)